Macquarie Group
IOVA icon

Macquarie Group’s Iovance Biotherapeutics IOVA Stock Holding History

Macquarie Group’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,791,235
Closed -$16M – 1705
2025
Q1 		$16M Buy
4,791,235
+40,301
+0.8% +$208K 0.02% 718
2024
Q4 		$35.2M Buy
4,750,934
+1,560,898
+49% +$14.5M 0.04% 505
2024
Q3 		$30M Buy
+3,190,036
New +$30.2M 0.03% 584
2024
Q2 		– Sell
-122,053
Closed -$1.81M – 2008
2024
Q1 		$1.81M Buy
+122,053
New +$1.42M ﹤0.01% 1248
2023
Q2 		– Sell
-55,835
Closed -$341K – 1690
2023
Q1 		$341K Sell
55,835
-674
-1% -$4.65K ﹤0.01% 1506
2022
Q4 		$361K Sell
56,509
-7,347
-12% -$57.4K ﹤0.01% 1551
2022
Q3 		$634K Sell
63,856
-2,537
-4% -$29.3K ﹤0.01% 1493
2022
Q2 		$733K Buy
66,393
+1,721
+3% +$22.6K ﹤0.01% 1542
2022
Q1 		$1.08M Buy
64,672
+7,019
+12% +$109K ﹤0.01% 1535
2021
Q4 		$1.1M Buy
57,653
+9,472
+20% +$209K ﹤0.01% 1537
2021
Q3 		$1.19M Sell
48,181
-1,700
-3% -$40.1K ﹤0.01% 1545
2021
Q2 		$1.3M Buy
49,881
+6,343
+15% +$165K ﹤0.01% 1543
2021
Q1 		$1.38M Buy
43,538
+4,609
+12% +$191K ﹤0.01% 1312
2020
Q4 		$1.81M Sell
38,929
-12,046
-24% -$478K ﹤0.01% 1135
2020
Q3 		$1.68M Sell
50,975
-1,189
-2% -$36.5K ﹤0.01% 1090
2020
Q2 		$1.43M Buy
52,164
+6,809
+15% +$224K ﹤0.01% 1112
2020
Q1 		$1.36M Sell
45,355
-16,137
-26% -$428K ﹤0.01% 1015
2019
Q4 		$1.7M Sell
61,492
-2,132
-3% -$48.5K ﹤0.01% 1084
2019
Q3 		$1.16M Buy
63,624
+34
+0.1% +$752 ﹤0.01% 1176
2019
Q2 		$1.56M Sell
63,590
-13,620
-18% -$205K ﹤0.01% 1084
2019
Q1 		$734K Buy
+77,210
New +$750K ﹤0.01% 1253

Other funds holding IOVA

MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Macquarie Group's IOVA Position: Q2 2025 in Review

Macquarie Group sold out of Iovance Biotherapeutics (IOVA) in Q2 2025, closing a stake of 4,791,235 shares — an estimated $16M sold.

Macquarie Group first reported a position in IOVA in Q1 2019 and held it in 21 quarters. The position peaked at $35.2M in Q4 2024. 254 funds tracked by Wall St. Rank hold IOVA as of Q2 2025.

  • Macquarie Group reported no remaining Iovance Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • Macquarie Group sold 4,791,235 Iovance Biotherapeutics shares in Q2 2025, an estimated $16M.
  • Macquarie Group first reported a position in Iovance Biotherapeutics in Q1 2019 and held it in 21 quarters.
  • Macquarie Group's Iovance Biotherapeutics position peaked at $35.2M in Q4 2024.
  • 254 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2025.

Based on Macquarie Group's 13F filing for Q2 2025, filed 14 Aug 2025.